Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.

Cancer immunology, immunotherapy : CII - 1 Apr 2022

Elias Esteban Enrique, Sarapura Martinez Valeria Judith, Amondarain Mikele, Colado Ana, Cordini Gregorio, Bezares Raimundo Fernando, Fernandez Grecco Horacio, Custidiano Maria Del Rosario, Sánchez Ávalos Julio César, Garate Gonzalo, Pavlovsky Miguel A, Borge Mercedes, Giordano Mirta, Gamberale Romina

Abstract excerpt

Venetoclax treatment has demonstrated efficacy and a safety profile in chronic lymphocytic leukemia (CLL) patients, however the emergence of resistant cells is a current complication. We and others, previously reported that the activation of CLL cells by signals that mimic microenvironment stimuli favors the upregulation of anti-apoptotic proteins from B cell lymphoma-2 (BCL-2) family that are not targeted by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Phosphatidylinositol 3-Kinases

Share to Sulfonamides

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34467417
DOI: 10.1007/s00262-021-03043-x
PMCID: PMC10992976

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.PMID 34467417Read ↗

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine SignalingSemantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?Semantic proximity Read ↗

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.Semantic proximity Read ↗

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.Semantic proximity Read ↗

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesSemantic proximity Read ↗

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesSemantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasSemantic proximity Read ↗

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.